Merck says vericiguat’s VICTORIA trial met primary endpoint

Each year nearly 30% of patients with chronic heart failure experience disease worsening. Credit: Pexels from Pixabay.



  • Merck says vericiguat’s VICTORIA trial met primary endpoint